Format

Send to

Choose Destination
Trop Med Infect Dis. 2019 Apr 18;4(2). pii: E67. doi: 10.3390/tropicalmed4020067.

Antiviral Therapy for the Next Influenza Pandemic.

Author information

1
WHO Collaborating Centre for Reference and Research on Influenza, VIDRL, Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia. Aeron.Hurt@influenzacentre.org.
2
Department of Microbiology and Immunology, University of Melbourne, Parkville, VIC 3010, Australia. Aeron.Hurt@influenzacentre.org.

Abstract

Influenza antivirals will play a critical role in the treatment of outpatients and hospitalised patients in the next pandemic. In the past decade, a number of new influenza antivirals have been licensed for seasonal influenza, which can now be considered for inclusion into antiviral stockpiles held by the World Health Organization (WHO) and individual countries. However, data gaps remain regarding the effectiveness of new and existing antivirals in severely ill patients, and regarding which monotherapy or combinations of antivirals may yield the greatest improvement in outcomes. Regardless of the drug being used, influenza antivirals are most effective when treatment is initiated early in the course of infection, and therefore in a pandemic, effective strategies which enable rapid diagnosis and prompt delivery will yield the greatest benefits.

KEYWORDS:

antivirals; influenza; pandemic; stockpile

PMID:
31003518
DOI:
10.3390/tropicalmed4020067
Free full text

Supplemental Content

Full text links

Icon for Multidisciplinary Digital Publishing Institute (MDPI)
Loading ...
Support Center